Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Reconsideration of Clinical and Histopathological Prognostic Factors in Breast Cancer Patients: A Single Center Experience

  • Tanriverdi, Ozgur (Department of Medical Oncology, Faculty of Medicine, Adnan Menderes University) ;
  • Meydan, Nezih (Department of Medical Oncology, Faculty of Medicine, Adnan Menderes University) ;
  • Barutca, Sabri (Department of Medical Oncology, Faculty of Medicine, Adnan Menderes University)
  • Published : 2014.01.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The clinical course of the neoplasm may vary due to both patient and tumor cell characteristics. Aim: The aim of this study was to research the influence of certain clinical and pathological features on the prognosis of early stage breast cancer. Materials and Methods: This study included 117 women that were treated and followed-up in between the years 2001-2011. The demographic, clinical and histopathological features of the cases were reviewed retrospectively. Statistical analysis: In categorical comparisons between groups, cross-tab statistics were provided and significance levels were estimated using chi-square test. Cox regression analysis, Pearson and Spearman correlation tests, and the Kaplan-Meier test were also used. Results: With an average of 35-months follow-up, the mean disease-free survival of patients was 91 months and the mean overall survival time was 132 months. In the whole study group, the disease-free survival rates were 88, 84, 83 and 52%, while the overall survival rates 95, 94, 83, and 83% within the first, third, fifth and tenth years, respectively. The disease-free and overall survival rates were decreased with increasing tumor grades, though this was not statistically significant. The presence of lymphovascular invasion, positive staining with Ki67 and postmenopausal status were associated with shorter disease-free and overall survival times. In multivariate analysis, only age and Her2/neu receptor status influenced the prognosis significantly. Conclusions: In parallel to clinical, histopathological, and immunohistochemical prognostic features in breast cancer, in this study positive Her2/neu receptor status, a previously accepted poor prognostic factor, was found to have positive influence after trastuzumab treatment.

Keywords

References

  1. Carter C, Allen C, Henson D (1989). Relation of tumor size, lymph node and survival in 24 740 breast cancer cases. Cancer, 63, 181-7. https://doi.org/10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H
  2. Curigliano G, Viale G, Bagnari V, et al (2009). Clinical relevance of Her2 overexpresion/ amplification in patients with small tumour size and node-negative breast cancer. J Clin Oncol, 27, 5693-99. https://doi.org/10.1200/JCO.2009.22.0962
  3. Dowsett M, Allred C, Knox J, et al (2008). Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor-2 (Her2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol, 26, 1059-65. https://doi.org/10.1200/JCO.2007.12.9437
  4. Drukker CA, Bueno-de-Mesquita JM, Retel VP, et al (2013). A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer, 133, 929-36. https://doi.org/10.1002/ijc.28082
  5. Dunnwold LK, Rossing MA, Li CI (2007). Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res, 9, 6-9.
  6. Early Breast Cancer Trialists' Collaborative Group (1998). Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet, 351, 1451-67. https://doi.org/10.1016/S0140-6736(97)11423-4
  7. Ferrero JM, Ramaioli A, Formento JL, et al (2000). p53 determination alongside classical prognostic factors in nodenegative breast cancer: An evaluation at more than 10-year follow- up. Ann Oncol, 11, 393-7. https://doi.org/10.1023/A:1008359722254
  8. Goldhirsch A, Wood WC, Gelber RD, et al (2007). Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol, 18, 1133-44. https://doi.org/10.1093/annonc/mdm271
  9. Gonzales-Angulo AM, Litton JK, Broglio KR, et al (2009). High risk of recurrence for patientswith breast cancer who have human epidermal growth factor receptor 2- positive, nodenegative tumors 1 cm or smaller. J Clin Oncol, 27, 5700-6. https://doi.org/10.1200/JCO.2009.23.2025
  10. Grann VR, Trovel AB, Zojualla NJ, et al (2005). Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer, 103, 2241-51. https://doi.org/10.1002/cncr.21030
  11. Joensuu H, Bono P, Kataja V, et al (2009). Fluorouracil, epirubisin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adhuvant treatments of breast cancer: final results of the FinHer study. J Clin Oncol, 27, 5685-92. https://doi.org/10.1200/JCO.2008.21.4577
  12. Jung KW, Won YJ, Kong HJ, et al (2013). Survival of korean adults patientsby stage at diagnosis, 2006-2010; national cancer registry study. Cancer Res Treat, 45, 162-71. https://doi.org/10.4143/crt.2013.45.3.162
  13. Kroger N, Milde-Langosh K, Riethdorf S, et al (2006). Prognostic and predictive effects of immunohistochemical factors in high risk primary breast cancer patients. Clin Cancer Res, 12, 159-68. https://doi.org/10.1158/1078-0432.CCR-05-1340
  14. Lai HW, Kuo SJ, Chen LS, et al (2011). Prognostic significance of triple negative breast cancer at tumor size 1 cm and smaller. Eur J Surg Oncol, 37, 18-24. https://doi.org/10.1016/j.ejso.2010.10.003
  15. Nishimura R, Arima N (2008). Is triple negative a prognostic factor in breast cancer? Breast Cancer, 15, 303-8. https://doi.org/10.1007/s12282-008-0042-3
  16. Rakha EA, Martin S, Lee AHS, et al (2012). The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer, 118, 3670-80. https://doi.org/10.1002/cncr.26711
  17. Reinke T (2013). Poor risk assessment limits breast cancer survival. Manag Care, 22, 6-7.
  18. Rodrigues MJ, Wassermann J, Albiges L, et al (2010). Trastuzumab treatment in T1ab, node-negative, human epidermal growth factor receptor- 2 -over-expressing breast carcinomas. J Clin Oncol, 28, 541-2. https://doi.org/10.1200/JCO.2010.29.7952
  19. Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman J (1989). Pathological prognostic fac-tors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinomas: a study of 644 patients with median follow-up of 18 years. J Clin Oncol, 7, 1239-51.
  20. Rosen PP, Groshen S, Kinne DW (1992). Survival and prognostic factors in node-negative breast cancer: results of long-term follow-up studies. J Natl Cancer Inst Monogr, 11, 159-62.
  21. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
  22. Smith I, Practer M, Gelber RD, et al (2007). 2-year follow- up of trastuzumab after adjuvant chemotherapy in Her2 positive breast cancer: a randomized controlled trial. Lancet, 39, 29-36.
  23. Taneja P, Maglic D, Kai F, et al (2010). Classical and novel prognostic markers for breast cancer and their clinical significance. Clin Med Insights: Oncol, 4, 15-34.
  24. Truong PT, Vinh-Hung V, Cserni G, et al (2008). The number of positive nodes and the ratio of positive to excised nodes are significant predictors of sur-vival in women with micrometastatic node-positive breast cancer. Eur J Cancer, 44, 1670-7. https://doi.org/10.1016/j.ejca.2008.05.011
  25. Viale G, Regan MM, Maiorano E, et al (2007). Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG- I-98. J Clin Oncol, 25, 3846-52. https://doi.org/10.1200/JCO.2007.11.9453
  26. Weigel MT, Dowsett M (2010). Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer, 17, 245-62. https://doi.org/10.1677/ERC-10-0136

Cited by

  1. Relationship of Body Mass Index with Prognosis in Breast Cancer Patients Treated with Adjuvant Radiotherapy and Chemotherapy vol.15, pp.10, 2014, https://doi.org/10.7314/APJCP.2014.15.10.4233
  2. Correlation between Ki67 and Histological Grade in Breast Cancer Patients Treated with Preoperative Chemotherapy vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10277
  3. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.1347
  4. Can Diffusion-Weighted Imaging and Related Apparent Diffusion Coefficient be a Prognostic Value in Women With Breast Cancer? vol.35, pp.2, 2017, https://doi.org/10.1080/07357907.2016.1267740